Skip to main content
SpringerLink
Log in

Novel protein kinases in pancreatic cell growth and cancer

  • Review Article
  • Published:
International Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

The network of enzymes that contribute to the signal transduction of extracellular factors in pancreatic cancer is ever increasing. The classical Raf-MEK-ERK signaling cascade plays a crucial role in the regulation of apoptosis, proliferation, and metastasis of pancreatic cancer. Phosphatidylinositide-3-kinase also contributes to growth and prevents apoptosis in pancreatic cancer cells, acting in part via its downstream targets, PKB/AKT and the FRAP/p70s6k signaling complex. Recently, members of the PKC family of serine threonine kinases have emerged as novel modulators of transformation and cell cycle progression of pancreatic cancers. The novel PKD family of serine threonine kinases has just been detected in pancreatic cancer and awaits its functional characterization in these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun 2001;280:992–997.

    Article  PubMed  CAS  Google Scholar 

  2. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344–352.

    Article  PubMed  CAS  Google Scholar 

  3. Wagner M, Lopez ME, Cahn M, Korc M. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer cell growth in vitro and in vivo. Gastroenterology 1998;114:798–807.

    Article  PubMed  CAS  Google Scholar 

  4. Seufferlein T, Van Lint J, Liptay S, Adler G, Schmid RM. Transforming growth factor alpha activates Ha-ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 1999;116:1441–1452.

    Article  PubMed  CAS  Google Scholar 

  5. Giehl K, Skripczynski B, Mansard A, Menke A, Gierschik P. Growth factor-dependent activation of the Ras-Raf-MEKMAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 2000;19:2930–2942.

    Article  PubMed  CAS  Google Scholar 

  6. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N, MEK/ERK signalling pahway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000;79:355–369.

    Article  PubMed  CAS  Google Scholar 

  7. Boucher MJ, Duchesne C, Laine J, Morisset J, Rivard N. cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition. Biochem Biophys Res Commun 2001;285:207–216.

    Article  PubMed  CAS  Google Scholar 

  8. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelialmesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001;61:4222–4228.

    PubMed  CAS  Google Scholar 

  9. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339–2342.

    PubMed  CAS  Google Scholar 

  10. Ding XZ, Adrian TE. MEK/ERK-mediated proliferation is negatively regulated by p38 map kinase in the human pancreatic cancer cell line, Panc-1. Biochem Biophys Res Commun 2001;282:447–453.

    Article  PubMed  CAS  Google Scholar 

  11. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000;90:39–44.

    Article  PubMed  CAS  Google Scholar 

  12. Ng SSW, Tsa MS, Chow S, Hedley DW. Inhibition phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451–5455.

    PubMed  CAS  Google Scholar 

  13. Ferrari S, Thomas G. S6 phosphorylation and the p70s6k/p85s6k. Crit Rev Bio Mol Biol 1994;29:385–413.

    Article  CAS  Google Scholar 

  14. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992;257:973–977.

    Article  PubMed  CAS  Google Scholar 

  15. von Manteuffel SR, Gingras AC, Ming XF, Sonenberg N, Thomas G. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogenactivated protein kinase. Proc Natl Acad Sci USA 1996;93:4076–4080.

    Article  Google Scholar 

  16. Chou MM, Blenis J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Curr Opin Cell Biol 1995;7:806–814.

    Article  PubMed  CAS  Google Scholar 

  17. Rousseau D, Gingras AC, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996;13:2415–2420.

    PubMed  CAS  Google Scholar 

  18. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999;59:3581–3587.

    PubMed  CAS  Google Scholar 

  19. Shah SA, Potter MW, Ricciardi R, Perugini RA, Callery MP. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J Surg Res 2001;97:123–130.

    Article  PubMed  CAS  Google Scholar 

  20. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636–3641.

    Article  PubMed  CAS  Google Scholar 

  21. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001;61:589–593. (This paper shows that AKT regulates IGF-IR expression in human pancreatic cancer cells as a downstream target of src and suggests that active AKT promotes the invasiveness of pancreatic cancer cells through the up-regulation of IGF-IR expression.)

    PubMed  CAS  Google Scholar 

  22. Hirata M, Tsuchida A, Iwao T, et al. Cholecystokinin regulates the invasiveness of human pancreatic cancer cell lines via protein kinase C pathway. Int J Oncol 1999;14:1129–1135.

    PubMed  CAS  Google Scholar 

  23. Trauzold A, Werman H, Arlt A, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001;20:4258–4269. (This manuscript demonstrates that protein kinase C protects pancreatic cancer cells from anti-CD95 and TRAIL-mediated apoptosis by inducing NFkappaB.)

    Article  PubMed  CAS  Google Scholar 

  24. Detjen KM, Brembeck FH, Welzel M, et al. Activation of protein kinase C alpha inhibits growth of pancreatic cancer cells via p21cip-mediated G(1) arrest. J Cell Sci 2000;113:3025–3035.

    PubMed  CAS  Google Scholar 

  25. Denham DW, Fran MG, Denham W, et al. Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 1998;124:218–223.

    PubMed  CAS  Google Scholar 

  26. Van Lint J, Rykx A, Maeda Y, et al. Protein Kinase D: an intracellular traffic regulator on the move. Trends Cell Biol 2002;12:193–200. (This review provides a comprehensive overview on the current state of PKD-research.)

    Article  PubMed  Google Scholar 

  27. Guha S, Rey O, Rozengurt E. Neurotension Induces Protein Kinase C-dependent Protein Kinase D Activation and DNA Synthesis in Human Pancreatic Carcinoma Cell Line PANC-1. Cancer Res 2002;62:1632–1640.

    PubMed  CAS  Google Scholar 

  28. Sturany S, Van Lint J, Mueller F, et al. Molecular cloning and characterization of the human protein kinase D2. J Biol Chem 2001;276:3310–3318.

    Article  PubMed  CAS  Google Scholar 

  29. Hayashi A, Seki N, Hattori A, Kozuma S, Saito T. PKCv, a new member of the protein kinase C family, composes a fourth subfamily with PKC. Biochim Biophys Acta 1999;1450:99–106.

    Article  PubMed  CAS  Google Scholar 

  30. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503–508.

    Article  PubMed  CAS  Google Scholar 

  31. Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G, Lutz MP. Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res 1998;58:3551–3554.

    PubMed  CAS  Google Scholar 

  32. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP Kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810–816.

    Article  PubMed  CAS  Google Scholar 

  33. Alexandre J, Raymond E, Armand JP. Rapamycin and CCI-779. Bull Cancer 1999;86:808–811.

    PubMed  CAS  Google Scholar 

  34. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Medicine 2002;8:128–135. (This paper describes the inhibition of metastatic tumor growth and angiogenesis in in vivo mouse models and the control of established tumors by the FRAP inhibitor, rapamycin. Rapmycin, which is also an immunosuppressant, may reduce the risk of recurrent or de novo cancer in transplant patients.)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Medical University of Ulm/Germany, Abt. Innere Medizin I, Medizinische Universitaetsklinik Ulm, Robert-Koch Str. 8, D-89081, Ulm, Germany

    Thomas Seufferlein

Authors
  1. Thomas Seufferlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Seufferlein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seufferlein, T. Novel protein kinases in pancreatic cell growth and cancer. Int J Gastrointest Canc 31, 15–21 (2002). https://doi.org/10.1385/IJGC:31:1-3:15

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/IJGC:31:1-3:15

Key Words

Search

Navigation